KLK1

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Health, FDA, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Epilepsy, TPA, AIS, Patient, Tissue plasminogen activator, Stroke, G&A, Investment, Therapy, Pharmacovigilance, Nektar Therapeutics, Research, KLK1, Biostatistics, NKTR, Trial of the century, DSM-IV codes, NIHSS, Amgen, Data management, Pharmacy, Food, Cubist Pharmaceuticals, Neurology, Rankine scale, Shanghai Pharmaceuticals, DMAC, Acquisition, University, Yale University, Psychiatry, MRS, ASTN, Takeda, Patent, Bangladesh Technical Education Board, Probability, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the year ended December 31, 2023.
  • Management will host a conference call Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2023 financial results.
  • Other income, net, was $1.9 million for the year ended December 31, 2023 compared to $0.4 million for 2022.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and full year quarter 2023 financial results on Wednesday, March 20, 2024, at 8:00 AM Eastern Time / 7:00 AM Central Time:

DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference

Retrieved on: 
Monday, January 29, 2024
Health, Neurology, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, DMAC, Patient, Poster, Conference, KLK1, AIS, American Heart

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke (AIS), today announced a poster presentation of the design and rationale for ReMEDy2, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the American Heart Association 2024 International Stroke Conference being held in Phoenix, AZ from February 7 – 9, 2024.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke (AIS), today announced a poster presentation of the design and rationale for ReMEDy2, the planned pivotal phase 2/3 trial of DM199 in AIS patients, at the American Heart Association 2024 International Stroke Conference being held in Phoenix, AZ from February 7 – 9, 2024.
  • The poster will be located in Poster Hall 5-6 (Poster Board CTP36).
  • Dr. Scott Kasner, ReMEDy2 trial National Principal Investigator, will be present to answer questions about the poster.
  • DiaMedica will also be exhibiting at the conference located in the main hall at booth 1021.

DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Health, FDA, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, TPA, Food, NIHSS, Investment, Clinical trial, DSM-IV codes, Patient, Research, AIS, DMAC, G&A, Stroke, Patent, Trial of the century, PPD, R, Hospital, ChromeOS, MRS, KLK1, Pharmaceutical industry, Cryptocurrency

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended September 30, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended September 30, 2023.
  • Management will host a conference call Tuesday, November 14, 2023, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and third quarter 2023 financial results.
  • These study modifications include focusing participant eligibility to those subjects with only moderate acute ischemic strokes in the anterior circulation.
  • DiaMedica Management will host a conference call and webcast to discuss its business update and third quarter 2023 financial results on Tuesday, November 14, 2023, at 8:00 AM Eastern Time / 7:00 AM Central Time:

DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023

Retrieved on: 
Thursday, November 9, 2023
Health, Clinical Trials, General Health, Pharmaceutical, Cardiology, Biotechnology, KLK1, Conference, DMAC, Pharmaceutical industry, Financial adviser

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, today announced that Rick Pauls, its President and CEO and Dave Wambeke, its Chief Business Officer will be participating in the 14th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 16, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, today announced that Rick Pauls, its President and CEO and Dave Wambeke, its Chief Business Officer will be participating in the 14th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 16, 2023.
  • Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.

DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

Retrieved on: 
Wednesday, June 21, 2023
FDA, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, DMAC, KLK1, Therapy, Stroke, Clinical trial, DSM-IV codes, AIS, Patient, Kidney, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, MD

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS) and that preparations are underway to resume the ReMEDy2 trial as soon as possible.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS) and that preparations are underway to resume the ReMEDy2 trial as soon as possible.
  • “​We are pleased that the FDA has fully lifted the clinical hold.
  • ​DM199, a synthetic formulation of the human tissue-1 kallikrein protein (KLK1), represents a novel approach to treating AIS patients, principally aimed at enhancing collateral blood flow in the brain tissues affected by the stroke,” said Rick Pauls, DiaMedica’s President and CEO.
  • “We look forward to re-engaging with our study sites and stroke expert principal investigators as we resume our ReMEDy2 trial as there is continued unmet need of new potential therapeutics for patients who have had an ischemic stroke,” said Kirsten Gruis, MD, DiaMedica’s Chief Medical Officer.

DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer

Retrieved on: 
Tuesday, April 11, 2023
Health, Neurology, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Acceleration, Collateral circulation, DMAC, Investment banking, Initial public offering, Employment, University, KLK1, Purple Heart, Stroke, The Purple Heart, Brain, AIS, Sale, Partner, Patient, CBO, United States Department of the Army, Iraq War, Capital Group Companies, Pharmaceutical industry, Security (finance)

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David Wambeke, as Chief Business Officer (CBO).

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David Wambeke, as Chief Business Officer (CBO).
  • In this position, he will lead business development, including financing and partnering strategies, and acceleration of prioritized development programs, as well as other business operations.
  • “Dave brings over 15 years of relevant life sciences, M&A, capital markets, and investor relations experience to DiaMedica.
  • Prior to joining Craig-Hallum, Mr. Wambeke was enlisted in the U.S. Army and served as an artilleryman and military police officer.

DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022

Retrieved on: 
Monday, November 7, 2022
FDA, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Chronic kidney disease, CEO, Kidney, KLK1, Conference, DMAC, Therapy, Nasdaq, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating in the 13th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 17, 2022.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO will be participating in the 13th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 17, 2022.
  • Investors and attendees that would like to schedule a meeting with DiaMedicas management can contact their Craig-Hallum representative to arrange a meeting.
  • DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases.
  • For more information visit the Companys website at www.diamedica.com .

DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference

Retrieved on: 
Monday, October 31, 2022
Biotechnology, Pharmaceutical, Health, Chronic kidney disease, Conference, DMAC, CEO, Credit, KLK1, Kidney, Nasdaq, Therapy, Credit Suisse, Pharmaceutical industry

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO, will present a corporate overview at the Credit Suisse 31st Annual Healthcare Conference, which will take place November 8 10, 2022 in Rancho Palos Verdes, California.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and CEO, will present a corporate overview at the Credit Suisse 31st Annual Healthcare Conference, which will take place November 8 10, 2022 in Rancho Palos Verdes, California.
  • Mr. Pauls is scheduled to present at 8:35 a.m. Eastern Time on November 9, 2022.
  • In addition to the presentation, Mr. Pauls will be available for one-on-one investor meetings throughout the conference.
  • DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases.

DiaMedica Therapeutics Provides Update on ReMEDy2 Trial

Retrieved on: 
Wednesday, October 26, 2022
Medical Supplies, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, TPA, U.S. Securities and Exchange Commission, Tissue plasminogen activator, Hypertension, Nitric oxide, Risk, Webcast, Chronic kidney disease, Vascular dementia, Therapy, Population, Stroke, Patient, Urine, Annual report, Inflammation, AIS, Neurogenesis, Private Securities Litigation Reform Act, Form 10-K, Goal, KLK1, Company, Retinopathy, Nature, File, Fibrosis, Oxidative stress, Hypotension, Terminology, FDA, COVID-19, Pharmaceutical industry

The ReMEDy2 trial is an adaptive design, randomized, double-blind, placebo-controlled trial studying the use of the Companys product candidate, DM199, to treat AIS patients.

Key Points: 
  • The ReMEDy2 trial is an adaptive design, randomized, double-blind, placebo-controlled trial studying the use of the Companys product candidate, DM199, to treat AIS patients.
  • DiaMedica believes that the proposed trial has the potential to serve as a pivotal registration study of DM199 in this patient population.
  • DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases.
  • While DiaMedica may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws.

DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations

Retrieved on: 
Wednesday, September 14, 2022
Biotechnology, Pharmaceutical, Health, CSL, U.S. Securities and Exchange Commission, Inflammation, Outline of health sciences, Employment, Lists of diseases, Chronic kidney disease, COVID-19, Fibrosis, Arthritis, FDA, Nitric oxide, Risk, Hypotension, Nature, Company, MSHS, DMAC, Form 10-K, Hypertension, Stroke, Therapy, Patient, BioCryst Pharmaceuticals, Letter, Dermatology, File, Retinopathy, CEO, Oxidative stress, BS, Terminology, Neurogenesis, Goal, Nasdaq, Private Securities Litigation Reform Act, AIS, Urine, Annual report, CCRP, SVP, KLK1, Vascular dementia, Kidney, George Washington University School of Medicine & Health Sciences, Pharmaceutical industry, Chiltern, Zoology

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Julie VanOrsdel Daves, MSHS, CCRP, as Senior Vice President (SVP), Clinical Development Operations.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Julie VanOrsdel Daves, MSHS, CCRP, as Senior Vice President (SVP), Clinical Development Operations.
  • Ms. Daves, a recognized leader in managing global clinical studies, has significant experience in all phases of clinical development and will complement DiaMedicas growing clinical team.
  • Julie brings nearly two decades of clinical development operations experience to DiaMedica across a wide breadth of pharmaceutical therapeutic areas, including Phase 3 pivotal programs.
  • Prior roles include leadership positions in clinical operations at Edgewise Therapeutics, miRagen Therapeutics, Chiltern, Array Biopharma, and BioCryst Pharmaceuticals.